Literature DB >> 3293554

Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression.

S Naidu1, M J Bresnan, D Griffin, S O'Toole, H W Moser.   

Abstract

Cyclophosphamide in a dosage of 350 to 700 mg/m2/d was administered for five to 11 days to four patients with childhood adrenoleukodystrophy (ALD) and to one patient with the adult cerebral form of the disease. The rate of neurologic progression in the four patients with childhood ALD did not differ from that of 167 untreated patients with childhood ALD surveyed previously.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3293554     DOI： 10.1001/archneur.1988.00520320032011

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


  10 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  X-linked adrenoleukodystrophy: first report of the Italian Study Group.

Authors:  A Di Biase; S Salvati; C Avellino; M Cappa; E Bertini; I Moroni; M Rimoldi; G Uziel
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 3.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

4.  A mouse model for X-linked adrenoleukodystrophy.

Authors:  J F Lu; A M Lawler; P A Watkins; J M Powers; A B Moser; H W Moser; K D Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

5.  Adrenoleucodystrophy.

Authors:  S H Green
Journal:  Arch Dis Child       Date:  1991-07       Impact factor: 3.791

Review 6.  Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.

Authors:  Johannes Berger; Aurora Pujol; Patrick Aubourg; Sonja Forss-Petter
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

7.  Progression of X-linked adrenoleukodystrophy under interferon-beta therapy.

Authors:  G C Korenke; H J Christen; B Kruse; D H Hunneman; F Hanefeld
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

Review 8.  Adrenomyeloneuropathy as a cause of primary adrenal insufficiency and spastic paraparesis.

Authors:  Monika Spurek; Regina Taylor-Gjevre; Stan Van Uum; Hasnain M Khandwala
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

Review 9.  Adrenoleukodystrophy: phenotypic variability and implications for therapy.

Authors:  H W Moser; A B Moser; K D Smith; A Bergin; J Borel; J Shankroff; O C Stine; C Merette; J Ott; W Krivit
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

10.  Unrelated allogeneic bone marrow transplant in adrenoleukodystrophy using CD34+ stem cell selection.

Authors:  Anupama Borker; Lolie C Yu
Journal:  Metab Brain Dis       Date:  2002-09       Impact factor: 3.584
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.